Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.